Maria Laggner

Maria Laggner

Auto-generated profile, based on publicly available information

Maria Laggner

Division of Thoracic Surgery, Medical University of Vienna, Vienna, Austria; Aposcience AG, Vienna, Austria

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2020 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
MLMaria Laggner
Maria Laggner
AGAlfred Gugerell
Alfred Gugerell
CBChristiane Bachmann
Christiane Bachmann
HHHelmut Hofbauer
Helmut Hofbauer
VVVera Vorstandlechner
Vera Vorstandlechner
hendrik jan ankersmithendrik jan ankersmit
hendrik jan ankersmit
Background: The recent concept of secretome-based tissue regeneration has profoundly altered the field of regenerative medicine and offers promising novel therapeutic options. In contrast to medicinal products with a single active substance, cell-derived secretomes comprise pleiotropic bioactive ingredients, representing a major obstacle for reproducible drug product efficacy and warranting patient safety. Good manufacturing practice (GMP)-compliant production guarantees high batch-to-batch consistency and reproducible efficacy of biological medicinal products, but different batches of cellular secretomes produced under GMP have not been compared yet, and suitable quality control parameters have not been established. To this end, we analyzed diverse biological and functional parameters of different batches produced under GMP of the secretome obtained from γ-irradiated peripheral blood mononuclear cells with proven tissue regenerative properties in infarcted myocardium, stroke, spinal cord injury, and skin wounds. Methods: We quantified key secretome ingredients, including cytokines, lipids, and extracellular vesicles, and functionally assessed potency in tube formation assay, ex vivo aortic ring sprouting assay, and cell-based protein and reporter gene assays. Furthermore, we determined secretome stability in different batches after 6 months of storage at various ambient temperatures. Results: We observed that inter-batch differences in the bioactive components and secretome properties were small despite considerable differences in protein concentrations and potencies between individual donor secretomes. Stability tests showed that the analytical and functional properties of the secretomes remained stable when lyophilisates were stored at temperatures up to + 5 °C for 6 months. Conclusions: We are the first to demonstrate the consistent production of cell-derived, yet cell-free secretome as a biological medicinal product. The results from this study provide the basis for selecting appropriate quality control parameters for GMP-compliant production of therapeutic cell secretomes and pave the way for future clinical trials employing secretomes in tissue regenerative medicine.

1 May 2021 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
PKPolina Kalinina
Polina Kalinina
VVVera Vorstandlechner
Vera Vorstandlechner
MBMaria Buchberger
Maria Buchberger
LELeopold Eckhart
Leopold Eckhart
BLBarbara Lengauer
Barbara Lengauer
Michael MildnerMichael Mildner
Michael Mildner

5 September 2022
Verified
Conference Paper
Closed access
MDMartin Direder
Martin Direder
Tamara WeissTamara Weiss
Tamara Weiss
DCDragan Copic
Dragan Copic
VVVera Vorstandlechner
Vera Vorstandlechner
KKKatharina Klas
Katharina Klas
Michael MildnerMichael Mildner
Michael Mildner
Despite decades of research, the driving forces behind keloids, an itching, painful and movement-restricting skin disorder, are still not fully u | POSTER

19 August 2020 in SSRN Electronic Journal
Verified
Preprint
Open access
PDF file
CVCecilia Veraar
Cecilia Veraar
MKMatthias Koschutnik
Matthias Koschutnik
CNChristian Nitsche
Christian Nitsche
MLMaria Laggner
Maria Laggner
DPDominika Polak
Dominika Polak
hendrik jan ankersmithendrik jan ankersmit
hendrik jan ankersmit
Background: Transcatheter aortic valve implantation (TAVI) is rapidly replacing cardiac surgery due to its minimal invasiveness and practicability. Midterm immunological studies on the biocompatibility of galactose-alpha-1,3-galactose (α - Gal)-carrying bioprosthetic heart valves (BHVs) for TAVI are not available. In this study we investigated whether BHVs employed for TAVI augment an α - Gal-specific antibody-dependent and antibody-independent immune response 3 months post TAVI. Methods: This prospective observational study included 27 patients with severe aortic valve stenosis undergoing TAVI and 10 patients with severe mitral valve regurgitation treated with a transcatheter MitraClip procedure. Serum samples were collected before and 90 days after treatment and analyzed for concentrations of α - Gal-specific IgG, IgG subclasses and IgE, complement C3a, NETosis specific CitH3, and the systemic inflammation markers sST2 and IL-33 via ELISA. Findings: Three months after TAVI we found significantly increased serum concentrations of α - Gal-specific IgG3, C3a, citH3 levels, and sST2 (p=0·002, p=0·001, p=0·025, and p=0·039, respectively). Sensitization of α - Gal-specific IgE antibodies occurred in 55% of all patients after TAVI. Interpretation: Our results indicate that TAVI elicits a specific humoral immune response against α - Gal and causes an unspecific humoral inflammation compared with patients undergoing MitraClip implantation. This observation will lead to a better understanding of post intervention morbidity and the long-term durability of bioprostheses and indicates that caution is appropriate when designing implantation strategies for younger patients.